| Symbol | IPSC |
|---|---|
| Name | CENTURY THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 3675 MARKET STREET, PHILADELPHIA, Pennsylvania, 19104, United States |
| Telephone | +1 267 817-5790 |
| Fax | — |
| — | |
| Website | https://www.centurytx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001850119 |
| Description | Century Therapeutics Inc is a biotechnology company developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with a plays a central role in the production of blood cells in the bone marrow. It is assembling a portfolio of allogeneic iNK and iT cell therapy product candidates across solid tumor and hematological malignancies. Additional info from NASDAQ: |
(99% Neutral) CENTURY THERAPEUTICS, INC. (IPSC) Announces Executive Departure
Read moreRussotti Gregory 🔴 sold 2.6K shares of Century Therapeutics, Inc. (IPSC) at $2.23 Transaction Date: Jun 12, 2026 | Filing ID: 000010
Read moreCarr Douglas 🔴 sold 1.7K shares of Century Therapeutics, Inc. (IPSC) at $2.23 Transaction Date: Jun 12, 2026 | Filing ID: 000014
Read morePfeiffenberger Brent 🔴 sold 13.8K shares of Century Therapeutics, Inc. (IPSC) at $2.24 Transaction Date: Jun 11, 2026 | Filing ID: 000012
Read moreCowan Chad 🔴 sold 358 shares of Century Therapeutics, Inc. (IPSC) at $2.24 Transaction Date: Jun 11, 2026 | Filing ID: 000010
Read moreRiva Alessandro 🟢 acquired 74.0K shares (1 derivative) of Century Therapeutics, Inc. (IPSC) at $2.24 Transaction Date: Jun 11, 2026 | Filing ID: 000006
Read moreQuimi Daphne 🟢 acquired 74.0K shares (1 derivative) of Century Therapeutics, Inc. (IPSC) at $2.24 Transaction Date: Jun 11, 2026 | Filing ID: 000002
Read moreMurphy Martin Patrick 🟢 acquired 74.0K shares (1 derivative) of Century Therapeutics, Inc. (IPSC) at $2.24 Transaction Date: Jun 11, 2026 | Filing ID: 000006
Read moreLee Han Myung 🟢 acquired 74.0K shares (1 derivative) of Century Therapeutics, Inc. (IPSC) at $2.24 Transaction Date: Jun 11, 2026 | Filing ID: 000002
Read moreBlackwell Kimberly 🟢 acquired 74.0K shares (1 derivative) of Century Therapeutics, Inc. (IPSC) at $2.24 Transaction Date: Jun 11, 2026 | Filing ID: 000002
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07243704 | Reducing the Burden of Cardiovascular Events With Antiplatelet Therapy in Patie… | Phase3 | Intracerebral Haemorrhage | Not_Yet_Recruiting | 2026-02-15 | 2029-02-14 | ClinicalTrials.gov |
| NCT07068061 | PER-SAF_PDOS (Performance and Safety of Polydioxanone Suture) | Na | Wrinkles | Not_Yet_Recruiting | 2025-09-01 | 2026-07-01 | ClinicalTrials.gov |
| NCT06255028 | A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune … | Phase1 | Systemic Lupus Erythematosus | Active_Not_Recruiting | 2025-02-06 | 2028-08-01 | ClinicalTrials.gov |
| NCT05768269 | A Study for Participants Previously Treated With Century Therapeutics Cellular … | — | Hematological Malignancy | Recruiting | 2024-04-29 | 2040-03-01 | ClinicalTrials.gov |
| NCT05336409 | A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies | Phase1 | R/R CD19-Positive B-Cell Malignancies | Terminated | 2023-01-24 | 2025-07-01 | ClinicalTrials.gov |
| NCT03571724 | A Study to Assess Changes in Cigarette Consumption During a Switch to Very Low … | Na | Tobacco Use | Completed | 2018-06-28 | 2019-03-08 | ClinicalTrials.gov |
| NCT03559725 | Evaluation of Abuse Liability of Very Low Nicotine (VLN) Mentholated Cigarettes | Phase1 | Tobacco Use | Completed | 2018-05-01 | 2018-10-04 | ClinicalTrials.gov |
| NCT04775836 | An EHR-based Platform To Facilitate Outcomes and Research Methods in Cerebrovas… | — | Stroke | Unknown | 2018-01-01 | 2021-12-31 | ClinicalTrials.gov |
| NCT02903862 | Health-eBrain Study | Na | Depression and Burden in Caregivers | Withdrawn | 2016-07-01 | 2017-07-01 | ClinicalTrials.gov |
| NCT02325388 | Pressure Sensing to Reduce the Risk of Pressure Ulcer Formation | Na | Pressure Ulcer | Completed | 2014-12-01 | 2018-05-10 | ClinicalTrials.gov |
| NCT01402609 | Assessing the Efficacy of an Electronic Discharge Communication Tool | Na | Other Diagnoses, Comorbidities, and Complications | Completed | 2011-09-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT01400815 | Randomized Trial to Evaluate the Effectiveness of X-22 as a Smoking Cessation A… | Phase2 | Smoking Cessation | Completed | 2011-07-01 | 2012-12-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Subject's UB mentholated filtered cigarettes | Other | Approved | Tobacco Use | COMPLETED | NCT03571724 |
| Subject's UB non-mentholated filtered cigarettes | Other | Approved | Tobacco Use | COMPLETED | NCT03571724 |
| Menthol Very Low Nicotine Cigarettes | Other | Approved | Tobacco Use | COMPLETED | NCT03571724 |
| Non-Menthol Very Low Nicotine Cigarettes | Other | Approved | Tobacco Use | COMPLETED | NCT03571724 |
| Usual care | Other | Approved | Other Diagnoses, Comorbidities, and Complications | COMPLETED | NCT01402609 |
| electronic discharge communication tool | Other | Approved | Other Diagnoses, Comorbidities, and Complications | COMPLETED | NCT01402609 |
| Usual care | Other | Approved | Other Diagnoses, Comorbidities, and Complications | COMPLETED | NCT01402609 |
| electronic discharge communication tool | Other | Approved | Other Diagnoses, Comorbidities, and Complications | COMPLETED | NCT01402609 |
| Usual care | Other | Approved | Other Diagnoses, Comorbidities, and Complications | COMPLETED | NCT01402609 |
| electronic discharge communication tool | Other | Approved | Other Diagnoses, Comorbidities, and Complications | COMPLETED | NCT01402609 |
| DANA | Other | Approved | Depression and Burden in Caregivers | WITHDRAWN | NCT02903862 |
| Mindoula | Other | Approved | Depression and Burden in Caregivers | WITHDRAWN | NCT02903862 |
| DANA | Other | Approved | Depression and Burden in Caregivers | WITHDRAWN | NCT02903862 |
| Mindoula | Other | Approved | Depression and Burden in Caregivers | WITHDRAWN | NCT02903862 |
| DANA | Other | Approved | Depression and Burden in Caregivers | WITHDRAWN | NCT02903862 |
| Mindoula | Other | Approved | Depression and Burden in Caregivers | WITHDRAWN | NCT02903862 |
| ForeSite PT™ system | Other | Approved | Pressure Ulcer | COMPLETED | NCT02325388 |
| ForeSite PT™ system | Other | Approved | Pressure Ulcer | COMPLETED | NCT02325388 |
| ForeSite PT™ system | Other | Approved | Pressure Ulcer | COMPLETED | NCT02325388 |
| Nicotine gum (C) | Other | Phase PHASE1 | Tobacco Use | COMPLETED | NCT03559725 |
| Usual Brand Menthol Cigarettes (B) | Other | Phase PHASE1 | Tobacco Use | COMPLETED | NCT03559725 |
| VLN menthol cigarettes (A) | Other | Phase PHASE1 | Tobacco Use | COMPLETED | NCT03559725 |
| Nicotine gum (C) | Other | Phase PHASE1 | Tobacco Use | COMPLETED | NCT03559725 |
| Usual Brand Menthol Cigarettes (B) | Other | Phase PHASE1 | Tobacco Use | COMPLETED | NCT03559725 |
| VLN menthol cigarettes (A) | Other | Phase PHASE1 | Tobacco Use | COMPLETED | NCT03559725 |
| Subject's UB mentholated filtered cigarettes | Other | Approved | Tobacco Use | COMPLETED | NCT03571724 |
| Subject's UB non-mentholated filtered cigarettes | Other | Approved | Tobacco Use | COMPLETED | NCT03571724 |
| Menthol Very Low Nicotine Cigarettes | Other | Approved | Tobacco Use | COMPLETED | NCT03571724 |
| Non-Menthol Very Low Nicotine Cigarettes | Other | Approved | Tobacco Use | COMPLETED | NCT03571724 |
| Active Control Cigarettes | Other | Phase PHASE2 | Smoking Cessation | COMPLETED | NCT01400815 |
| X-22 Smoking Cessation Product | Other | Phase PHASE2 | Smoking Cessation | COMPLETED | NCT01400815 |
| Active Control Cigarettes | Other | Phase PHASE2 | Smoking Cessation | COMPLETED | NCT01400815 |
| X-22 Smoking Cessation Product | Other | Phase PHASE2 | Smoking Cessation | COMPLETED | NCT01400815 |
| No Intervention | Other | Preclinical | Hematological Malignancy | RECRUITING | NCT05768269 |
| PDO suture | Other | Approved | Wrinkles | NOT_YET_RECRUITING | NCT07068061 |
| PDO suture | Other | Approved | Wrinkles | NOT_YET_RECRUITING | NCT07068061 |
| Lymphodepleting Chemotherapy | Drug | Phase PHASE1 | R/R CD19-Positive B-Cell Malignancies | TERMINATED | NCT05336409 |
| IL-2 | Other | Phase PHASE1 | R/R CD19-Positive B-Cell Malignancies | TERMINATED | NCT05336409 |
| CNTY-101 | Other | Phase PHASE1 | R/R CD19-Positive B-Cell Malignancies | TERMINATED | NCT05336409 |
| Lymphodepleting Chemotherapy | Drug | Phase PHASE1 | Systemic Lupus Erythematosus | ACTIVE_NOT_RECRUITING | NCT06255028 |
| IL-2 | Other | Phase PHASE1 | Systemic Lupus Erythematosus | ACTIVE_NOT_RECRUITING | NCT06255028 |
| CNTY-101 | Other | Phase PHASE1 | Systemic Lupus Erythematosus | ACTIVE_NOT_RECRUITING | NCT06255028 |
| Placebo | Other | Phase PHASE3 | Intracerebral Haemorrhage | NOT_YET_RECRUITING | NCT07243704 |
| Aspirin 75 mg daily | Other | Phase PHASE3 | Intracerebral Haemorrhage | NOT_YET_RECRUITING | NCT07243704 |
| Placebo | Other | Phase PHASE3 | Intracerebral Haemorrhage | NOT_YET_RECRUITING | NCT07243704 |
| Aspirin 75 mg daily | Other | Phase PHASE3 | Intracerebral Haemorrhage | NOT_YET_RECRUITING | NCT07243704 |
| No Intervention | OTHER | Preclinical | Hematological Malignancy | RECRUITING | NCT05768269 |
| Lymphodepleting Chemotherapy | DRUG | Phase PHASE1 | Systemic Lupus Erythematosus | ACTIVE_NOT_RECRUITING | NCT06255028 |
| IL-2 | BIOLOGICAL | Phase PHASE1 | Systemic Lupus Erythematosus | ACTIVE_NOT_RECRUITING | NCT06255028 |
| CNTY-101 | BIOLOGICAL | Phase PHASE1 | Systemic Lupus Erythematosus | ACTIVE_NOT_RECRUITING | NCT06255028 |